1-Hydroxy-2-azido-6-phenyloxyhex-4-yn | 1026489-50-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-Hydroxy-2-azido-6-phenyloxyhex-4-yn
• 英文别名: 2-Azido-6-phenoxyhex-4-yn-1-ol
• CAS: 1026489-50-8
• 化学式: C₁₂H₁₃N₃O₂
• 分子量: 231.254
• InChiKey: JSJCSJRIRIDSBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-Hydroxy-2-azido-6-phenyloxyhex-4-yn 在 水 、 碳酸氢钠 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 N-[4-[(1-hydroxy-6-phenoxyhex-4-yn-2-yl)sulfamoyl]phenyl]acetamide
  参考文献：
  名称：

  Development of New Carboxylic Acid-Based MMP Inhibitors Derived from Functionalized Propargylglycines

  摘要：

  A series of carboxylic acids were prepared from a propargylglycine scaffold and tested for efficacy as matrix metalloproteinase (MMP) inhibitors. Detailed SAR for the series is reported for four enzymes within the MMP family. The inhibitors were typically potent against collagenase-3 (MMP-13) and gelatinase A (MMP-2), while they spared collagenase-1 (MMP-1) and only moderately inhibited stromelysin (MMP-3). Compound 40 represents a typical inhibition profile of a compound with reasonable potency. Introduction of polar groups was required in order to generate inhibitors with acceptable water solubility, and this often resulted in a loss of potency as in compound 63. High serum protein binding proved to be a difficult hurdle with many compounds such as 48 showing > 99% binding. Some compounds such as 64 displayed similar to 90% binding, but no reliable method was discovered for designing molecules with low protein binding. Finally, selected data regarding the pharmacokinetic behavior of these compounds is presented.

  DOI：

  10.1021/jm000477l
• 作为产物：
  描述：

  苯基炔丙基醚 在 正丁基锂 、 sodium azide 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-Hydroxy-2-azido-6-phenyloxyhex-4-yn
  参考文献：
  名称：

  Development of New Carboxylic Acid-Based MMP Inhibitors Derived from Functionalized Propargylglycines

  摘要：

  A series of carboxylic acids were prepared from a propargylglycine scaffold and tested for efficacy as matrix metalloproteinase (MMP) inhibitors. Detailed SAR for the series is reported for four enzymes within the MMP family. The inhibitors were typically potent against collagenase-3 (MMP-13) and gelatinase A (MMP-2), while they spared collagenase-1 (MMP-1) and only moderately inhibited stromelysin (MMP-3). Compound 40 represents a typical inhibition profile of a compound with reasonable potency. Introduction of polar groups was required in order to generate inhibitors with acceptable water solubility, and this often resulted in a loss of potency as in compound 63. High serum protein binding proved to be a difficult hurdle with many compounds such as 48 showing > 99% binding. Some compounds such as 64 displayed similar to 90% binding, but no reliable method was discovered for designing molecules with low protein binding. Finally, selected data regarding the pharmacokinetic behavior of these compounds is presented.

  DOI：

  10.1021/jm000477l

文献信息

• Alkenyl- and alkynl-containing metalloprotease inhibitors
  申请人：The Procter & Gamble Co.

  公开号：US06197770B1

  公开（公告）日：2001-03-06

  Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): where X, W, Z, A, G, R1, R2, R3, R4, R5, R5′ and k have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof Also described are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

  本发明涉及一类金属蛋白酶抑制剂化合物，用于治疗由这些酶活性过度引起的疾病。具体来说，这些化合物具有以下式（I）的结构，其中X、W、Z、A、G、R1、R2、R3、R4、R5、R5'和k的含义如规范中所述。本发明还包括上述式的光学异构体、顺反异构体和对映体，以及这些化合物的药用盐、生物水解酰胺、酯和亚酰胺。还描述了包含这些化合物的药物组合物，以及使用这些化合物或药物组合物来治疗或预防与金属蛋白酶相关的疾病的方法。
• [EN] ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEASES, CONTENANT ALCENYLE ET ALCYNALE
  申请人：PROCTER & GAMBLE

  公开号：WO2000051975A1

  公开（公告）日：2000-09-08

  Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to Formula (I) where X, W, Z, A, G, R?1, R2, R3, R4, R5, R5'¿ and k have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of said formula, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also described are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

  本发明涉及一种金属蛋白酶抑制剂化合物，其能够有效治疗由这些酶过度活性引起的疾病。特别地，该化合物具有如公式（I）所示的结构，其中X，W，Z，A，G，R1，R2，R3，R4，R5，R5'和k具有规范中描述的含义。本发明还包括该公式的光学异构体、对映异构体和对映体，以及其药学上可接受的盐、生物水解酰胺、酯和亚酰胺。还描述了包含这些化合物的药物组合物，以及使用这些化合物或药物组合物治疗或预防金属蛋白酶相关疾病的方法。
• ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP1165501A1

  公开（公告）日：2002-01-02
• US6197770B1
  申请人：——

  公开号：US6197770B1

  公开（公告）日：2001-03-06
• Development of New Carboxylic Acid-Based MMP Inhibitors Derived from Functionalized Propargylglycines
  作者：Michael G. Natchus、Roger G. Bookland、Matthew J. Laufersweiler、Staszek Pikul、Neil G. Almstead、Biswanath De、Michael J. Janusz、Lily C. Hsieh、Fei Gu、Matthew E. Pokross、Vikram S. Patel、Susan M. Garver、Sean X. Peng、Todd M. Branch、Selane L. King、Timothy R. Baker、David J. Foltz、Glen E. Mieling

  DOI：10.1021/jm000477l

  日期：2001.3.1

  A series of carboxylic acids were prepared from a propargylglycine scaffold and tested for efficacy as matrix metalloproteinase (MMP) inhibitors. Detailed SAR for the series is reported for four enzymes within the MMP family. The inhibitors were typically potent against collagenase-3 (MMP-13) and gelatinase A (MMP-2), while they spared collagenase-1 (MMP-1) and only moderately inhibited stromelysin (MMP-3). Compound 40 represents a typical inhibition profile of a compound with reasonable potency. Introduction of polar groups was required in order to generate inhibitors with acceptable water solubility, and this often resulted in a loss of potency as in compound 63. High serum protein binding proved to be a difficult hurdle with many compounds such as 48 showing > 99% binding. Some compounds such as 64 displayed similar to 90% binding, but no reliable method was discovered for designing molecules with low protein binding. Finally, selected data regarding the pharmacokinetic behavior of these compounds is presented.